Levoketoconazole

Brand names: Recorlev · Active ingredient: Levoketoconazole

In short: RECORLEV is indicated for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Limitations of Use RECORLEV is not approved for the treatment of fungal infections.

Forms & strengthsTablets: 150 mg, round, pink, film-coated, and imprinted in black ink with “LEV” above “150” on one side; the other side is plain.
LabelXeris Pharmaceuticals, Inc.
Label updatedJun 26, 2026

What is Levoketoconazole used for?

RECORLEV is indicated for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative.

Limitations of Use

RECORLEV is not approved for the treatment of fungal infections. The safety and effectiveness of RECORLEV for the treatment of fungal infections have not been established.

⚠ Boxed warning (FDA's strongest warning)

Hepatotoxicity

• Cases of hepatotoxicity with a fatal outcome or requiring liver transplantation have been reported with use of oral ketoconazole. Some patients had no obvious risk factors for liver disease. Serious hepatotoxicity has been reported in patients receiving RECORLEV

.

• RECORLEV is contraindicated in patients with cirrhosis, acute liver disease or poorly controlled chronic liver disease, recurrent symptomatic cholelithiasis, a prior history of drug induced liver injury due to ketoconazole or any azole antifungal therapy that required discontinuation of treatment, or extensive metastatic liver disease

.

• Evaluate liver enzymes prior to and during treatment. Interrupt RECORLEV treatment immediately if signs of hepatotoxicity occur

.

QT Prolongation

• RECORLEV is associated with dose-related QT interval prolongation. QT interval prolongation may lead to life-threatening ventricular dysrhythmias such as torsades de pointes

.

• Coadministration of RECORLEV with other drugs that prolong the QT interval associated with ventricular arrhythmias, including torsades de pointes, and use in patients with a prolonged QTcF interval of greater than 470 msec at baseline, history of torsades de pointes, ventricular tachycardia, ventricular fibrillation, or long QT syndrome (including first-degree family history) are contraindicated

.

• Perform an ECG and correct hypokalemia and hypomagnesemia prior to and during treatment. Temporarily discontinue RECORLEV if QTcF interval exceeds 500 msec

[Dosage and Administration (

2.1,

2.3,

2.4)].

Levoketoconazole dosage

Obtain baseline liver tests [alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin]. Carefully consider the risks and potential benefits of initiating RECORLEV in patients with AST or ALT above normal but less than or equal to 3 times the upper limit of normal

.

Obtain baseline electrocardiogram (ECG)

.

Correct hypokalemia and hypomagnesemia prior to starting RECORLEV

.

Initiate dosage at 150 mg orally twice daily, with or without food

.

Titrate the dosage by 150 mg daily, no more frequently than every 2-3 weeks based on 24-hour urine free cortisol levels and patient tolerability

. Monitor cortisol levels from at least two 24-hour urine free cortisol collections every 2-3 weeks until an adequate clinical response is achieved.

The maximum recommended dosage is 1200 mg per day, administered as 600 mg twice daily.

The dosage may be reduced to 150 mg once daily if needed for reasons of tolerability

.

Once the maintenance dosage is achieved, monitor cortisol levels from at least two 24-hour urine free cortisol collections at least every 1-2 months or as indicated.

If 24-hour urine free cortisol levels remain above the upper normal limit after treatment with the maximum recommended dosage of 1200 mg per day, or the patient cannot tolerate treatment with RECORLEV, consider discontinuing RECORLEV and switching patient to another therapy.

Perform the following monitoring during RECORLEV treatment. Refer to Dosage Interruptions and Modifications below for recommendations pertaining to management of liver, cortisol, or ECG abnormalities

.

Hepatotoxicity

Serious hepatotoxicity has been reported in patients receiving RECORLEV, and therefore frequent monitoring of liver tests is recommended.

Monitor liver enzymes and bilirubin weekly for at least 6 weeks after starting RECORLEV, every 2 weeks for the next 6 weeks, monthly for the next 3 months, and then as clinically indicated.

After any dose interruption or dose increase, monitor on a weekly basis until a stable dosage is achieved

.

QT Prolongation

Conduct an ECG before each dose increase. After a stable dosage is established, monitor routinely for an effect on the QT interval.

Monitor blood potassium and magnesium levels periodically during treatment

.

Hypocortisolism

Monitor 24-hour urine free cortisol, morning serum or plasma cortisol, and patient’s signs and symptoms for hypocortisolism periodically during RECORLEV treatment

.

Hepatotoxicity

Refer to

Table 1 for management of hepatotoxicity

.

ALT or AST | Total Bilirubin | Recommendation

≥ 5 x ULN | Any value | Permanently discontinue RECORLEV.

≥ 3 x ULN | > 2 x ULN | Permanently discontinue RECORLEV.

≥ 3 to < 5 x ULN | ≤ 2 x ULN | Temporarily discontinue RECORLEV. …

How to take Levoketoconazole — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Monitoring

Instruct patients on the importance of laboratory monitoring and adherence to their return-visit schedule

.

Liver Injury

Inform patients that RECORLEV may cause liver injury. Advise patients of the signs and symptoms of hepatotoxicity (e.g., right upper quadrant pain associated with nausea, unusual fatigue, signs of jaundice, unusual bruising or bleeding). Advise patients to contact their healthcare provider immediately for signs or symptoms of hepatotoxicity. Advise patients that liver tests will be measured before treatment and periodically thereafter. Advise patients to avoid excessive alcohol use while taking RECORLEV

.

QT Prolongation

Inform patients that RECORLEV may cause QT prolongation. Advise patients to contact their healthcare provider immediately for signs or symptoms of QT prolongation, which include severe lightheadedness (pre-syncope) or fainting (syncope). Advise patients that an ECG will be taken before treatment and periodically thereafter. Advise patients that potassium and magnesium disturbances may require correction to aid in preventing QT interval prolongation

. …

Warnings & precautions

Do not take this medicine if: RECORLEV is contraindicated in patients:

With cirrhosis, acute liver disease or poorly controlled chronic liver disease, baseline AST or ALT greater than 3 times the upper limit of normal, recurrent symptomatic cholelithiasis, a prior history of drug induced liver injury due to ketoconazole or any azole antifungal therapy that required discontinuation of treatment, or extensive metastatic liver disease

.

Taking drugs that cause QT prolongation associated with ventricular arrhythmias, including torsades de pointes

.

With a prolonged QTcF interval of greater than 470 msec at baseline, history of torsades de pointes, ventricular tachycardia, ventricular fibrillation, or long QT syndrome (including first-degree family history)

.

With known hypersensitivity to levoketoconazole, ketoconazole or any excipient in RECORLEV

.

Taking certain drugs that are sensitive substrates of CYP3A4 or CYP3A4 and P-gP

.

Cases of hepatotoxicity with a fatal outcome or requiring liver transplantation have been reported with the use of oral ketoconazole, the racemic mixture from which levoketoconazole is derived. Some patients had no obvious risk factors for liver disease. Serious hepatotoxicity has been reported in patients receiving RECORLEV, irrespective of the dosages used or the treatment duration. Drug-induced liver injury (peak ALT or AST greater than 3 times upper limit of normal) occurred in 13% of patients using RECORLEV.

RECORLEV is contraindicated in patients with cirrhosis, acute liver disease or poorly controlled chronic liver disease, baseline AST or ALT greater than 3 times the upper limit of normal, recurrent symptomatic cholelithiasis, a prior history of drug induced liver injury due to ketoconazole or any azole antifungal therapy that required discontinuation of treatment, or extensive metastatic liver disease

. …

Levoketoconazole side effects

The following clinically significant adverse reactions are described elsewhere in the labeling:

Hepatotoxicity

QT Prolongation

Hypocortisolism

Hypersensitivity Reactions

Risks related to Decreased Testosterone

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of RECORLEV was evaluated in a multicenter, randomized-withdrawal study (Study 1) and in a multicenter, single-arm, open-label study (Study 2). During the two studies, 166 patients were exposed to RECORLEV, of which 104 patients were exposed for more than 6 months and 51 patients were exposed for at least 1 year. In both studies, most patients took RECORLEV twice daily in total daily dosages ranging from 300 mg to 1200 mg

.

Adverse reactions, excluding hepatic injury, reported in ≥10% of patients treated with RECORLEV in Study 1 are presented in

Table 2listed in order of overall decreasing frequency of events.

N = total number of patients, n = number of patients experiencing the event, (%) = proportion of patients experiencing the event.

aHemorrhage/contusion includes blood urine present, epistaxis, eye hemorrhage, gingival bleeding, hematoma, hematuria, hemorrhoidal hemorrhage, melena, and scleral hemorrhage. …

Drug interactions

Levoketoconazole is a strong CYP3A4 inhibitor, as well as an inhibitor of the drug transporters P-gp, OCT2, and MATE1 in vivo. In vitro, levoketoconazole inhibits CYP2B6 and CYP2C8. Concomitant use of RECORLEV with drugs that are substrates of these CYP enzymes and transporters may increase the risk of adverse reactions of these drugs.

Consult the approved product labeling for drugs that are substrates of CYP3A4, P-gp, OCT2, and MATE1 prior to initiating therapy with RECORLEV.

Table 6 presents drugs affected by RECORLEV that are contraindicated or not recommended for use during RECORLEV use. It also includes the clinical impact and management recommendations for concomitant use of RECORLEV with atorvastatin and metformin.

aThe drugs listed are substrates for CYP3A4 and/or P-gp. Other metabolism and/or transporter pathways may also contribute to elimination of the substrate drug. Consult the approved product labeling for the substrate drug for more information.

bStrong CYP3A4 inhibitor

.

cBased on clinical drug interaction study with levoketoconazole.

CYP3A4 or CYP3A4 and P-gp Substrates

aThat May Prolong QT

Clinical Impact | Increases risk of QT prolongation and torsades de pointes. …

About this medicine

RECORLEV (levoketoconazole) tablets contain levoketoconazole as the active ingredient. Levoketoconazole is the 2S,4R- enantiomer derived from racemic ketoconazole and is a cortisol synthesis inhibitor.

The chemical name of levoketoconazole is 2S,4R cis-1-acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl] methoxyl]phenyl] piperazine.

The molecular formula of levoketoconazole is C

26H

28Cl

2N

4O

4with a molecular mass of 531.43 g/mol.

Levoketoconazole is a white or almost white crystalline powder. It is very slightly soluble in water but soluble in aqueous solutions below pH 2.

RECORLEV tablets for oral administration contain 150 mg of levoketoconazole and the following inactive ingredients: colloidal silicon dioxide, lactose monohydrate, magnesium stearate, modified corn starch, and silicified microcrystalline cellulose. The non-functional pink film-coating contains iron oxide red, macrogol/polyethylene glycol 3350, polyvinyl alcohol partially hydrolyzed, talc, and titanium dioxide. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID d4c5fead-bc4a-fb02-e053-2a95a90ae4fc. Read the full official label on DailyMed.